AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...
AbbVie plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday, months after its experimental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback